The annual Abortion Statistics for England and Wales: 2022 has been provisionally delayed from 22 June 2023 until May 2024. This is due to a backlog in the HSA4 form processing, which the publication is based on. Legal abortions: rates by Primary Care Organisation by age. Rates per 1,000 in age group. Age not stated have been distributed pro-rata across age group 20-24. Rates for under 16 are based on populations 13-15. Rates for all ages, under 18 and 35 and over are based on populations 15-44, 15-17 and 35-44 respectively. External links: https://www.gov.uk/government/collections/abortion-statistics-for-england-and-wales

Number of induced abortions, rates of induced abortions per 1,000 females of same age group, proportions of induced abortions across age groups, and ratios of induced abortions per 100 live births, by age group of patient, 1987 to 2000.

🇬🇧 영국 English The annual Abortion Statistics for England and Wales: 2022 has been provisionally delayed from 22 June 2023 until May 2024. This is due to a backlog in the HSA4 form processing, which the publication is based on. Legal abortions: rates by Primary Care Organisation by age. Rates per 1,000 in age group. Age not stated have been distributed pro-rata across age group 20-24. Rates for under 16 are based on populations 13-15. Rates for all ages, under 18 and 35 and over are based on populations 15-44, 15-17 and 35-44 respectively. External links: https://www.gov.uk/government/collections/abortion-statistics-for-england-and-wales

We evaluated the current practices of abortion providers giving anti-D prophylaxis to RhD negative women undergoing first trimester medical abortion and factors that influenced the decision. We also examined RhD management strategies that could be safely adopted. A Steering Committee of abortion providers drafted a questionnaire on anti-D prophylaxis practices and perceptions. The 28-question survey, hosted online from December 2022 to December 2023, targeted international abortion providers. Almost 62% of respondents perform medical abortion during the first trimester (up to 12 weeks of amenorrhoea [WA]), while 32.8% provide it during the second trimester (13 to 26 WA). Among providers, 55.8% administer anti-D prophylaxis to all RhD negative women during first trimester medical abortions, 25.5% provide it selectively, and 18.6% do not administer it at all. Providers who do not administer IgG anti-D rely on national guidelines (51.2%), hospital protocols (16.3%), or both (7.0%), citing early gestational age (36.5%) and insufficient evidence (22.9%) as reasons. The primary reason for administering IgG anti-D was preventing risks in future pregnancies (52.7%). Yet, 59.1% expressed interest in changing their anti-D prophylaxis practices during early abortion. This study highlights the huge variations in anti-D prophylaxis practices during first trimester medical abortion. These discrepancies mirror differences in national and international guidelines and underscore the need for robust clinical evidence to determine the gestational age limits for alloimmunization risk and support protocol updates. We surveyed anti-D prophylaxis practices for RhD-negative women undergoing first-trimester medical abortion. Results show wide variations reflecting inconsistent national and international guidelines, highlighting the need for robust evidence to define alloimmunization risk and update protocols.

Abortion was legalized in Nepal in 2002; however, despite evidence of safety and quality provision of medical abortion (MA) pills by pharmacies in Nepal and elsewhere, it is still not legal for pharmacists to provide medication abortion in Nepal. However, pharmacies often do provide MA, but little is known about who seeks abortions from pharmacies and their experiences and outcomes. The purpose of this study is to understand the experiences of women seeking MA from a pharmacy, abortion complications experienced, and predictors for denial of MA. Data was collected from women seeking MA from four pharmacies in two districts of Nepal in 2021–2022. Data was collected at baseline (N = 153) and 6 weeks later (N = 138). Using descriptive results and multi-variable regression models, we explore differences between women who received and did not receive MA and predictors of denial of services. Most women requesting such pills received MA (78%), with those who were denied most commonly reporting denial due to the provider saying they were too far along. There were few socio-demographic differences between groups, with the exception of education and gestational age. Women reported receiving information on how to take pills and what to do about side effects. Just under half (45%) of women who took pills reported no adverse symptoms after taking them and only 13% sought care. Most women seeking MA from pharmacists in Nepal are receiving services, information, and having few post-abortion symptoms. This study expands the previous limited research on pharmacy provision of MA in Nepal using a unique dataset that recruits women at the time of abortion seeking and follows them over time, overcoming potential biases present in other study designs. This suggests that expansion of the law to allow pharmacy distribution would increase accessibility and reflect current practice.

Socio-demographic characteristics of the 15 Women and their Partners.